3 Cheap Obesity Stocks to Buy ASAP – 9/12

Company: Viking Therapeutics (SYM: VKTX)

Look at Viking Therapeutics (SYM: VKTX), for example.

Now trading at $57.80, we strongly believe it could easily rally back to $70, near-term. All as it nears Phase 3 trials for its obesity treatment, VK2735. In fact, as noted by the company, “We are advancing this compound into Phase 3 development,” CEO Brian Lian said, as noted in a company press release, adding that “we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year.”

Company: Structure Therapeutics (SYM: GPCR)

Structure Therapeutics (SYM: GPCR) just announced that its 2b obesity treatment study for GSBR-1290 would start in the fourth quarter of the year. In a prior study, GSBR-1290 “demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks,”according to a company press release. 

According to JPMorgan, “We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035. GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.”

Company: Altimmune (SYM: ALT)

There’s also Altimmune (SYM: ALT), whose pemvidutide treatment led to weight loss while preserving lean mass. That alone set it apart from the competition, with reports that Wegovy and Zepbound can lead to significant loss of muscle mass.

As noted in a company press release, “Preservation of lean mass may reduce risk of falls and fractures, development of co-morbidities, and rates of all-cause mortality, particularly in individuals over the age of 60,” said Scott Harris, M.D., Chief Medical Officer. 

“Our data demonstrates pemvidutide’s class-leading lean mass preservation, superior to that reported historically with diet and exercise.”